NCT04961359View on ClinicalTrials.gov

Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

July 3, 2021

Primary Completion Date

December 12, 2021

Study Completion Date

April 6, 2023

Conditions
Coronavirus
Interventions
BIOLOGICAL

Recombinant new coronavirus vaccine (CHO cell) group

Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).

BIOLOGICAL

Recombinant new coronavirus vaccine (CHO cells) placebo group

Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.

Trial Locations (1)

411228

Hunan Provincial Center for Disease Control and Prevention, Changsha

All Listed Sponsors
lead

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

INDUSTRY